Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548529
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
HER2 Expression of HER2 Affibody-based PETCT to Predict Response in Bladder Cancer Patients Treated With ADC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Al18F-HER2-BCH PETCT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To use the molecular PET radionuclide F-18 labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None